Minister of State for Road Transport, Highways,
Shipping and Chemicals & Fertilizers, Shri Mansukh Mandaviya has said in a
statement that the impact of GST has been positive and constructive on Pharma
The Minister gives details to establish the positive
impact of GST on pharma sector such as the annual turnover of the Pharma
sector, the exports and the annual drug approvals before and after GST.
Minister Mandaviya attributed this positive impact
post-GST to removal of complexity of taxes, ease of doing business resulting in
decrease in manufacturing cost and creation of a single market under ‘One
Nation, One Tax’ regime for all stakeholders with equal chance towards
To go into details:
Before GST, Annual Turnover of the Pharma
Sector (as on 31.05.2017) was Rs 1,14,231 crores while after GST, the
Annual Turnover of Pharma sector (as on 31.05.2018) touched Rs 1,31,312 crores,
which is 6% higher than the Pre-GST regime.
Exports from Pharma Sector during 2016-17 were Rs 2,75,852
crores while post-GST, in the year 2017-18, they were recorded at Rs 3,03,526
crores, which is 10% higher than the Pre-GST Regime. The Minister added that as
per estimates, the export figure for the current year is likely to be Rs
3,27,700 crores, which will be almost 12% higher than the export figure of
Pre-GST regime (2016-17).
Further, it was informed that there has been a
significant jump in number of Drug Approvals from 7,857
before GST (01.07.2016 to 30.06.2017) to 10,446 post-GST (01.07.2017 to
Shri Mandaviya informed
that due to discontinuation of Central Sales Tax post-GST, it will reduce
transaction costs, as inter-state transaction between two dealers will become
tax neutral. Now, the pharma companies can consolidate their warehouses at
strategic locations, effecting a reduction in cost of distribution. As a
result, it will benefit warehouse strategy and improve supply chain efficiency
in pharma sector, the Minister explained.